C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000062032.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page announces that the Ministry of Health, Labour and Welfare has issued a safety alert regarding the hepatitis C antiviral drug "Sobriard Capsule 100mg" due to reported deaths related to elevated bilirubin levels. Following three domestic fatality cases causally linked to the drug, the product labeling has been revised and healthcare providers have been instructed to provide immediate warnings. Key measures include regular blood bilirubin monitoring during treatment, discontinuation if abnormalities occur, continued observation after treatment cessation, and patient guidance to seek immediate medical consultation if symptoms such as jaundice or dark urine appear.
